My Account Log in

4 options

Glutamate-related biomarkers in drug development for disorders of the nervous system : workshop summary / Diana E. Pankevich, Miriam Davis, and Bruce M. Altevogt, rapporteurs ; Forum on Neuroscience and Nervous System Disorders, Board of Population Health and Public Health Practice, Institute of Medicine of the National Academies.

EBSCOhost Academic eBook Collection (North America) Available online

View online

Ebook Central Academic Complete Available online

View online

NCBI Bookshelf Available online

View online

National Academies Press Available online

View online
Format:
Book
Author/Creator:
Institute of Medicine (U.S.).
Contributor:
Pankevich, Diana E.
Davis, Miriam.
Altevogt, Bruce M.
Institute of Medicine (U.S.). Forum on Neuroscience and Nervous System Disorders.
Institute of Medicine (U.S.). Board of Population Health and Public Health Practice.
Language:
English
Subjects (All):
Glutamic acid--Pharmacokinetics.
Glutamic acid.
Central nervous system--Diseases.
Central nervous system.
Physical Description:
1 online resource (74 p.)
Edition:
1st ed.
Place of Publication:
Washington, D.C. : National Academies Press, 2011.
Language Note:
English
Summary:
Glutamate is the most pervasive neurotransmitter in the central nervous system (CNS). Despite this fact, no validated biological markers, or biomarkers, currently exist for measuring glutamate pathology in CNS disorders or injuries. Glutamate dysfunction has been associated with an extensive range of nervous system diseases and disorders. Problems with how the neurotransmitter glutamate functions in the brain have been linked to a wide variety of disorders, including schizophrenia, Alzheimer's, substance abuse, and traumatic brain injury. These conditions are widespread, affecting a large portion of the United States population, and remain difficult to treat. Efforts to understand, treat, and prevent glutamate-related disorders can be aided by the identification of valid biomarkers. The Institute of Medicine's Forum on Neuroscience and Nervous System Disorders held a workshop on June 21-22, 2010, to explore ways to accelerate the development, validation, and implementation of such biomarkers. This book investigates promising current and emerging technologies, and outlines strategies to procure resources and tools to advance drug development for associated nervous system disorders. Moreover, this report highlights presentations by expert panelists, and the open panel discussions that occurred during the workshop.
Contents:
""Front Matter""; ""Reviewers""; ""Contents""; ""1 Introduction""; ""2 Overview of the Glutamatergic System""; ""3 Glutamate Biomarkers""; ""4 Treatment Implications of Biomarkers""; ""5 Challenges and Opportunities""; ""Appendix A: References""; ""Appendix B: Registered Attendees""; ""Appendix C: Agenda""
Notes:
Description based upon print version of record.
Includes bibliographical references and index.
ISBN:
0-309-21224-3
1-283-21345-1
9786613213457
0-309-21222-7
OCLC:
923283605

The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.

Find

Home Release notes

My Account

Shelf Request an item Bookmarks Fines and fees Settings

Guides

Using the Find catalog Using Articles+ Using your account